[Clinical efficacy of the dietary supplement Astracit-Asfarma as a synergistic adjuvant to standard therapy for the elimination of residual fragments after endoscopic and shock wave lithotripsy in patients with urolithiasis (a pilot study)].

Plain-language guide to PMID 42417324 (2025): open-label randomized controlled trial of Copper (Supplement) in 100 patients.

Key Facts

PMID: 42417324
Journal: Urologiia (Moscow, Russia : 1999)
Year: 2025
Study type: Randomized Controlled Trial
Authors: Fomkin R N et al. (4 authors)

What This Study Did, in Plain Language

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Who Took Part

The abstract describes 100 patients taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

A prospective, randomised, comparative, open-label study was conducted involving 100 patients with nephro-ureterolithiasis who underwent planned lithotripsy using SWL or RIRS.

Patients were randomised into three equal groups: group 1 - SWL + standard therapy + dietary supplement "Astracit - Asfarma"; group 2 - RIRS + standard therapy + dietary supplement Astracit-Asfarma; group 3 (control): subgroup 3A SWL + standard therapy only; subgroup 3B RIRS + standard therapy only.

How the Study Was Run

The researchers set it up as a randomized, open-label and pilot study.

The patients were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Everyone knew when Copper (Supplement) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

What Was Measured

The subject headings attached to it are Lithotripsy, Dietary Supplements, Potassium Citrate, Pilot Projects, Urolithiasis, Citric Acid and Magnesium Compounds.

The authors tagged it with the keywords SFR (stone-free rate), magnesium citrate, metaphylactics and residual fragments.

What This Means in Plain Language

The paper is a randomized, open-label and pilot study of Copper (Supplement) in 100 patients.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Urologiia (Moscow, Russia : 1999)), a journal based in Russia (Federation).

More context: the Copper (Supplement) compound page, all human trials.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Copper (Supplement) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.